久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Wuhan, China

    Main Sales Markets: North America,Asia

  • Sample Provided: no

    Payment Terms: L/C

    Indications:

    • Treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
    • Treatment of chronic idiopathic constipation (CIC) in adults.

    Mechanism of Action: Linaclotide and its active metabolite bind to and activate the guanylate cyclase-C (GC-C) receptor on the luminal surface of the intestinal epithelium. This activation leads to increased concentrations of cyclic guanosine monophosphate (cGMP), which subsequently leads to the activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased chloride and bicarbonate secretion into the intestine. This increased fluid secretion helps soften stool and facilitate bowel movements.

    Pharmacokinetics:

    • Absorption: Minimally absorbed from the gastrointestinal tract.
    • Distribution: N/A due to minimal systemic absorption.
    • Metabolism: Degraded within the gastrointestinal tract to its active metabolite.
    • Excretion: Excreted primarily in the feces.

    Form: Linaclotide API is typically available as a white to off-white powder.

Send your message to this supplier
  • From:
  • To:
    HYBIO PHARMACEUTICAL CO., LTD.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service